| abstract |
The current invention comprises an approach to solving the clinicalnproblem of restenosis, which involves the administration of thenantiproliferative antineoplastic agent, cladribine, to patients undergoingnPTCA or stent implantation. In one embodiment of the invention, cladribinenis administered to patients systemically, either subcutaneously ornintravenously. In another embodiment of the invention, cladribine is boundnto the surface of a stent by means of incorporation within either anbiodegradable or biostable polymeric coating. Alternatively, cladribinencould be incorporated into a stent constructed with a grooved reservoir. |